Pharmacokinetics of IS-5-MN after Oral and Intravenous Administration in Patients with Hepatic Failure
Isosorbide-5-mononitrate (IS-5-MN) possesses complete absolute bioavailability due to the absence of any first-pass effect  in contrast to isosorbide dinitrate (ISDN) [2, 6,7, 8] which therefore has to be administered carefully in patients with impaired liver function, since higher concentrations than normal were found in these patients . The aim of the present study was to evaluate the role of the liver in the fate of IS-5-MN and its two metabolites, isosorbide-5-mononitrate-2-glucuro-nide (IS-5-MN-2-glu) and isosorbide (IS). The results obtained in the liver patients were compared with those of a group of six healthy volunteers.
KeywordsLiver Cirrhosis Renal Clearance None None Volunteer Group Impaired Liver Function
Unable to display preview. Download preview PDF.
- 2.Abshagen U, Betzien G, Endele R, Kaufmann B, Neugebauer G (1985) Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. Eur J Clin Pharmacol (in press)Google Scholar
- 3.Betzien G, Kaufmann B, Schneider B, Ritschel WA (1985) Evaluating blood level curves: A comprehensive approach with KINPAK. Harvey Whitney, Cincinnati (in press)Google Scholar